PrEP availability and Access Options in Australia

E. Wright
ARV Guidelines Session 2: PrEP
ASHM Conference, Brisbane 2015

Efficacy of HIV Prevention Strategies

<table>
<thead>
<tr>
<th>Study</th>
<th>Effect Size, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ART for prevention; HPTN 052, 5 years</td>
<td>96 (73-99)</td>
</tr>
<tr>
<td>ART for prevention; HPTN 052, 10 years</td>
<td>93 (87-99)</td>
</tr>
<tr>
<td>PrEP for MSM: the PROUD demo project</td>
<td>56 (42-70)</td>
</tr>
<tr>
<td>PrEP for MSM: the BEAT project</td>
<td>56 (42-70)</td>
</tr>
<tr>
<td>Consistent condom use, P-T sex, heterosexual discordant couples</td>
<td>56 (42-70)</td>
</tr>
<tr>
<td>PrEP for MSM: discordant couples</td>
<td>56 (42-70)</td>
</tr>
<tr>
<td>Consistent condom use, P-T sex, MSM</td>
<td>54 (38-66)</td>
</tr>
<tr>
<td>PrEP for heterosexuals; TDF2</td>
<td>63 (21-84)</td>
</tr>
<tr>
<td>Medical male circumcision</td>
<td>39 (6-60)</td>
</tr>
<tr>
<td>PrEP for MSM: IPERGA</td>
<td>31 (1-51)</td>
</tr>
<tr>
<td>Microbicide-CAP/Ghana</td>
<td>31 (1-51)</td>
</tr>
<tr>
<td>HIV vaccine/RV144</td>
<td>31 (1-51)</td>
</tr>
</tbody>
</table>

E. Wright
ARV Guidelines Session 2: PrEP
ASHM Conference, Brisbane 2015

PrEP Access options in Australia: “legal”

- Three PrEP Demonstration Projects
  - Approximately 600 places on Eastern seaboard only
  - Funded by State Departments of Health and study drug donated by Gilead Sciences
- Truvada self-importation with script from doctor
  - Informal estimates only
  - Victoria, approximately 100 people
  - Recently WA Health issued directive to support practitioners in this process
  - Great leadership
  - Other States may also pursue this approach
- Some States are paying for PrEP for highly vulnerable individuals
  - Including Medicare ineligible HIV+ people

PrEP Access options in Australia: “Other”

- Truvada importation without script
  - Informal estimates only
  - Victoria, ? 40
- Informal use of Truvada from friends and partners
- Presenting for NPEP on single or repeated occasions
  - Anecdotal
  - Not ideal for person presenting, healthcare provider, or the service

Current status of Truvada in TGA approval process for use as PrEP

- TGA approval => PBS subsidization
  - Linear submission approach taken by Gilead
    - TGA result due late 2015
    - Did have the option of taking a parallel TGA and PBS submission approach
    - Possible PBS listing in 2017 if TGA listing successful

Guidelines/Programs
- WHO
- CDC/DHHS
- Australia
- South Africa
- Kenya
- Thailand
- Brazil

Cost Truvada: A $900 month

F= Filing  L= licensed

Open label extension study
New clinical trial
Demonstration study
Studies closed- futility

Map: freeworldmaps.net

PrEP Access options in Australia: “legal”

PrEP Access options in Australia: “Other”

Current status of Truvada in TGA approval process for use as PrEP

- TGA approval => PBS subsidization
  - Linear submission approach taken by Gilead
    - TGA result due late 2015
    - Did have the option of taking a parallel TGA and PBS submission approach
    - Possible PBS listing in 2017 if TGA listing successful

Guidelines/Programs
- WHO
- CDC/DHHS
- Australia
- South Africa
- Kenya
- Thailand
- Brazil

Cost Truvada: A $900 month

F= Filing  L= licensed

Open label extension study
New clinical trial
Demonstration study
Studies closed- futility

Map: freeworldmaps.net
**Future options for Truvada Access**

**Access Truvada through research grant applications**
- NHMRC & other funding bodies
- Using CTN and purchase generic Truvada
- Time and intense competition for funding are critical issues for this option

**State and Commonwealth allocate funding**
- States currently fund PEP (non-PBS subsidised)
- PEP services and funding allocations could transition to PrEP provision for PEP re-representers as an urgent priority
- Commonwealth could provide funding to pay for Truvada until it receives TGA approval and PBS listing

**Other options**
- Gilead could provide Truvada free of charge for individuals outside of research projects
- TGA asks Gilead to urgently submit Truvada to PBAC for consideration of PBS subsidisation